Core Viewpoint - Mindray Medical's performance growth has slowed down since the second half of 2023 due to external economic factors, but the company remains optimistic and is focused on overcoming challenges through innovation and strategic adjustments [1][2]. Group 1: Performance and Financials - Mindray Medical hosted a research event with 382 institutions and 713 participants, discussing the company's performance and future strategies [1]. - Since its A-share listing in 2018, Mindray has achieved seven consecutive years of revenue and net profit growth, with 2024 revenue and net profit reaching 2.2 times and 2.5 times that of 2019, respectively [1]. - The company maintains a leading position in global market share for key products such as monitors, anesthesia machines, ventilators, defibrillators, blood products, and ultrasound devices [1]. Group 2: Research and Development - Mindray Medical invests approximately 10% of its revenue annually into R&D, with a record high investment of 4.008 billion yuan in 2024 [2]. - The R&D team consists of 5,000 members, positioning the company as a leader among domestic medical device firms and ensuring competitiveness in both domestic and international markets [2]. - The company focuses on high-end market demands, ranking third in the U.S. market for monitors and anesthesia machines, while also expanding into European and other overseas markets [2]. Group 3: Innovation and Technology - Mindray is actively integrating IT and AI technologies into its operations, creating differentiated advantages in smart healthcare [2]. - The application of vertical large models in ICU settings has improved diagnostic efficiency, with AI image reading accuracy exceeding 98% and efficiency being ten times that of manual processes [2]. - Historical experiences indicate that Mindray has successfully navigated challenges such as the 2008 financial crisis and the 2015 medical industry restructuring through policy adaptation and technological innovation [2].

因消息面利好，医疗器械近日受到关注。同类费率最低档的医疗器械ETF基金（159797）受冲高回落跌0.54%，盘中一度涨近2%， 持续溢价交易，近5日有3日"吸金"，今日盘中再度净流入！ 消息面上，国监局网站7月3日消息，日前，药监局发布优化全生命周期监管支持高端医疗器械创新发展的有关举措。该举措涵盖优 化特殊审批程序、完善分类和命名原则等十个方面的内容，旨在全力支持高端医疗器械重大创新，促进新技术、新材料、新工艺和 新方法在医疗健康领域的应用，满足人民群众健康需求，提升我国高端医疗器械的国际竞争力。 此外，高层发布通知，决定7月6日起，在行政采购活动中对部分自欧盟进口的医疗器械采取相关措施：采购人采购预算金额4500万 元人民币以上的医疗器械时，确需采购进口产品的，在履行法定程序后，应当排除欧盟企业（不包括在华欧资企业）参与；对于参 与的非欧盟企业，其提供的自欧盟进口的医疗器械占比不得超过项目合同总金额的50%；上述措施不适用于仅自欧盟进口的医疗器 械能够满足采购需求的采购项目。 医疗器械ETF基金（159797）标的指数成分股多数飘绿：热景生物跌超5%，迈瑞医疗跌超2%，乐普医疗、贝瑞基因跌超1%。上涨 ...

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing-Changping Life Science Forum opened, focusing on the layout of pharmaceutical research and the transformation of original achievements, with 14 major pharmaceutical health industry projects signed in Changping District [1] - Major projects include investments from companies such as Mindray Medical, Diyi Group, Yourui Bio, and others, as well as innovative collaborations with institutions like Shantou University and the National Research Institute of High-Performance Medical Devices [1][2] - The Beijing Future Pharmaceutical Industry Chain Research Institute was unveiled, aiming to support key technology collaboration and promote international development of the pharmaceutical industry [1] Group 2 - A joint initiative was launched among Tsinghua University, Peking University, China Agricultural University, and Beijing University of Chemical Technology to drive breakthroughs in biomedicine and synthetic biology, enhancing China's position in the global pharmaceutical value chain [2] - The "Support Measures for the Development of the Pharmaceutical Health Industry in the Changping Group of the China (Beijing) Free Trade Pilot Zone" were announced, focusing on cross-border R&D cooperation and aligning with international standards [2] - Changping District has established a complete industrial chain from basic research to terminal medical services, with an average annual growth rate of 9.3% in pharmaceutical health industry revenue over the past three years, projected to reach 104 billion yuan in 2024, a year-on-year increase of 14.3% [2][3] Group 3 - The district has seen continuous innovation, with four key technologies selected as major scientific achievements for the 2025 Zhongguancun Forum, and 27 cell and gene therapy pipelines entering clinical stages, accounting for 5% of the national total [3] - The Zhongguancun synthetic biology manufacturing industry cluster has attracted 121 innovative enterprises, and the "Future City" health industry has formed a 10 billion yuan cluster [3] - Changping District aims to enhance the ecosystem of industrial elements and improve service quality, striving to make the Life Science Park a globally competitive hub for the pharmaceutical health industry [3]

Group 1 - Foreign institutions conducted a total of 4,766 research visits to A-share companies in the first half of 2025, with over 1,000 visits to companies on the Shenzhen Main Board, ChiNext, and STAR Market [2][3] - Huichuan Technology was the most favored A-share company, receiving 485 visits from foreign institutions, followed by Mindray Medical with 299 visits [3] - Point72, a prominent hedge fund, led the research visits with 116 in the first half of 2025, focusing on 84 companies including Huichuan Technology, Xiaogoods City, and Aopute [3] Group 2 - Multiple foreign institutions hold an optimistic view on the performance of A-shares in the second half of 2025, citing strong market resilience and increased confidence in Chinese assets [3][4] - Morgan Stanley Fund believes that the current external environment does not pose substantial pressure on A-shares, viewing short-term disturbances as manageable [4] - Invesco's CIO for mainland China and Hong Kong anticipates the continuation and expansion of the "old for new" consumption policy, which is expected to drive economic growth in the coming months [4]

Group 1 - The core point of the announcement is that Ever Union (H.K.) Limited has completed its share reduction plan, selling a total of 5,000,000 shares of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. between July 3 and July 4, 2025 [1][4] - The share reduction was executed through block trading at a price range of 213.47 to 213.59 yuan per share, representing 0.41% of the total shares [1][2] - After the reduction, Ever Union's total shareholding decreased from 51,482,379 shares (4.25% of total shares) to 46,482,379 shares (3.83% of total shares) [3][4] Group 2 - The company confirms that the reduction of shares by Ever Union does not affect the company's governance structure or ongoing operations [4] - The company has fulfilled its information disclosure obligations regarding the progress of the share reduction as required by relevant regulations [4]

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-026 深圳迈瑞生物医疗电子股份有限公司 关于股东股份减持计划实施完成的公告 股东 Ever Union（H.K.）Limited 保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股东减持情况 1、股份来源：公司首次公开发行股票前持有的股份 | 股东名称 | 减持方式 | 减持期间 | 减持价格区间 | 减持股数 | 占总股 | | --- | --- | --- | --- | --- | --- | | | | | （元/股） | （股） | 本比例 | | Ever Union | 大宗交易 | 2025年7月3日至7 月4日 | 213.47-213.59 | 5,000,000 | 0.41% | 2、股东减持股份情况 注：Ever Union未在法律法规禁止减持的期间减持。 3、股东本次减持前后持股情况 | 股东名称 | 股份性质 | 本次减持前持有股份 | 占总股本 | 本次减持后持有股份 | 占总股本 | | --- | --- | --- | --- | --- | --- | | | | ...

Core Viewpoint - The performance of the CSI All Index for Medical Care Equipment and Services has shown mixed results, with a slight increase on the day but a decline over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI All Index for Medical Care Equipment and Services rose by 0.21% to 13,548.3 points, with a trading volume of 19.92 billion [1]. - Over the past month, the index has decreased by 1.41%, by 2.78% over the past three months, and by 1.24% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the medical care sector, reflecting the overall performance of these securities [1]. - The index was established on December 31, 2004, with a base point of 1,000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: Mindray Medical (9.65%), United Imaging (8.18%), Aier Eye Hospital (7.43%), Aimeike (3.42%), Huatai Medical (3.23%), Yuyue Medical (2.81%), New Industry (2.79%), Lepu Medical (2.69%), Meinian Onehealth (2.06%), and Shandong Pharmaceutical Glass (1.9%) [1]. Group 4: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.10%) and the Shanghai Stock Exchange (39.90%) [1]. - The entire sample of the index is focused on the pharmaceutical and healthcare sector, with a 100% allocation [1]. Group 5: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the index include various Southern and Tianhong funds, as well as ETFs from multiple asset management companies [2].

Company Overview - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. specializes in the research, manufacturing, marketing, and service of medical devices [1] - The main products include life information and support products, in vitro diagnostic products, medical imaging products, electrophysiology and vascular intervention products, and other products [1] Financial Performance - As of the latest quarterly report for Q1 2025, the company achieved operating revenue of 8.237 billion yuan, a year-on-year decrease of 12.12% [1] - The net profit for the same period was 2.629 billion yuan, reflecting a year-on-year decline of 16.81% [1] - The gross profit margin stands at 62.53% [1] Market Position - The closing stock price on July 4 was 223.8 yuan, with a rise of 1.63% [1] - The rolling price-to-earnings (PE) ratio is 24.36, while the industry average PE ratio is 51.05 [1][2] - The total market capitalization is 271.344 billion yuan [1] Capital Flow - On July 4, the net outflow of main funds was 10.2821 million yuan, with a total outflow of 148.5139 million yuan over the past five days [1]

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Core Insights - The company reported a revenue of 36.726 billion yuan in 2024, reflecting a growth of 5.14%, with a net profit attributable to shareholders of 11.668 billion yuan, up by 0.74% [1] - In Q4 2024, the company experienced a revenue decline of 5.08% to 7.241 billion yuan, while net profit surged by 40.99% to 1.031 billion yuan [1] - The first quarter of 2025 saw a revenue drop of 12.12% to 8.237 billion yuan, with net profit decreasing by 16.81% to 2.629 billion yuan [1] Financial Performance - The overall gross margin for 2024 was 63.14%, a decrease of 1.08%, primarily due to changes in business structure and product pricing adjustments [2] - The company’s operating cash flow for 2024 was 12.432 billion yuan, an increase of 12.38% [1] - The gross margin for Q1 2025 improved by 6.57 percentage points to 62.53%, indicating that short-term adjustments may have been largely absorbed [2] Business Segments - The Life Information and Support segment generated 13.557 billion yuan in 2024, a decline of 11.11%, but the minimally invasive surgery business grew by over 30% [3] - The In Vitro Diagnostics segment achieved a revenue of 13.765 billion yuan, up by 10.82%, despite domestic challenges due to policy changes [3] - The Medical Imaging segment reported a revenue of 7.498 billion yuan, reflecting a growth of 6.60%, with high-end ultrasound models contributing significantly [3] International Expansion - The company’s international business grew by 21.28% in 2024, accounting for approximately 45% of total revenue, driven by high-end customer acquisition and local platform development [2] - The In Vitro Diagnostics international business saw over 30% growth, with local production projects initiated in 13 countries [3] Research and Development - The company maintained high R&D investment levels, with 4.008 billion yuan in 2024, representing 10.91% of revenue [4] - As of March 31, 2025, the company had applied for approximately 12,000 patents, with 5,973 patents granted [4] Shareholder Returns - The company distributed a total cash dividend of 7.602 billion yuan in 2024, with a cash dividend ratio of 65.15% [4] - A mid-term profit distribution plan for 2025 proposes a cash dividend of 1.710 billion yuan, reflecting strong profitability and commitment to shareholder returns [4]